Aliskiren plus hydrochlorothiazide versus irbesartan, amlodipine, or hydrochlorothiazide alone in obese adults with hypertension inadequately controlled on hydrochlorothiazide

Phase 3, randomised, double-blind trial of aliskiren, hydrochlorothiazide, irbesartan and amlodipine in hypertension (HTN), essential hypertension and obesity (4 arms), sponsored by Novartis. Primary endpoints: Change from baseline in mean sitting diastolic blood pressure and Change from baseline in mean sitting systolic blood pressure. Started Aug 2005; status: completed.